Advertisement

Topics

ESMO 2017: Osimertinib improves progression-free survival in patients with EGFR mutated lung cancer

02:49 EDT 9 Sep 2017 | ecancermedicalscience

Osimertinib improves progression-free survival by 54% compared to standard first line therapy in patients with EGFR mutated non-small-cell lung cancer (NSCLC), according to late-breaking results from the FLAURA trial presented today at the ESMO 2017...

Original Article: ESMO 2017: Osimertinib improves progression-free survival in patients with EGFR mutated lung cancer

NEXT ARTICLE

More From BioPortfolio on "ESMO 2017: Osimertinib improves progression-free survival in patients with EGFR mutated lung cancer"

Quick Search
Advertisement
 

Relevant Topics

Lung Cancer
Lung cancer is the uncontrolled cell growth in tissues of the lung. Originating in the lungs, this growth may invade adjacent tissues and infiltrate beyond the lungs. Lung cancer, the most common cause of cancer-related death in men and women, is respons...

Gilotrif (afatinib)
GILOTRIF (afatinib) is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L8...